NR4A1 and breast cancer: In 2010, the American Society of Clinical Oncology (ASCO) updated its adjuvant breast cancer guideline to recommend that all postmenopausal women with hormone receptor–positive breast cancer use an AI either alone or before or after tamoxifen to reduce their risk of recurrence.